# Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes

Study · id `cardio:ct-nct06759922` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06759922](<https://clinicaltrials.gov/study/NCT06759922>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06759922

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 172 participants.

## Technical summary

Registry record NCT06759922. Randomized; no masking; primary purpose treatment. Start 2025-01-01 (actual); primary completion 2025-03-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 172 participants (enrolled count; ClinicalTrials.gov record NCT06759922, source copy `cardio:ctgov-nct06759922-2026-04-14`, retrieved 2026-10-26)
- Started: 2025-01-01 (actual) (ClinicalTrials.gov record NCT06759922, source copy `cardio:ctgov-nct06759922-2026-04-14`, retrieved 2026-10-26)
- Primary completion: 2025-03-30 (actual) (ClinicalTrials.gov record NCT06759922, source copy `cardio:ctgov-nct06759922-2026-04-14`, retrieved 2026-10-26)
- Completion: 2025-06-30 (actual) (ClinicalTrials.gov record NCT06759922, source copy `cardio:ctgov-nct06759922-2026-04-14`, retrieved 2026-10-26)
- Countries: Pakistan (ClinicalTrials.gov record NCT06759922, source copy `cardio:ctgov-nct06759922-2026-04-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06759922-2026-04-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Tab Metformin + Tab Glimepiride
- Intervention (Drug): Tab Metformin + Tab Empagliflozin
- Intervention (Drug): Tab Metformin +Tab Sitagliptin
- Intervention (Drug): Tab Metformin + Tab Empagliflozin + Tab Sitagliptin
- Lead sponsor: Bahria University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Bahria University (`cardio:org-bahria-university`)

## Provenance

Content hash: 3089cf8effbeeaad7b020798326d3ef972ebabd3cde7c9811fa0be5837062ed2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
